Urokinase thrombolysis

PreclinicalSmall molecule

TThe First Affiliated Hospital of Zhengzhou University

Urokinase thrombolysis is one of 51 small molecule programs targeting Ischemic stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Acute Ischemic StrokeRecruiting

Ischemic StrokePreclinical

Active, not recruiting

Acute Ischemic StrokePreclinical

Recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 2

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 3

Aggrastat

MMedicure

Phase 3

4 4

Rhtnk-Tpa

CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Phase 3

1 5

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 6

SGLT-2 Inhibitors

Novo Nordisk

Phase 3

1 7

PPA Intervention

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

1 8

SP-8203

SShin Poong Pharmaceutical Co. Ltd.

Phase 3

3 9

Y-6

BBeijing Tiantan Hospital

Phase 3

2 10

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Acute Ischemic Stroke

NCT07047326

Clinical

Trials by Indication[1]

Stroke1 trial

Thrombolysis of Urokinase for Minor Stroke

Completed·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT04420351·1,005 enrolled

Acute Ischemic Stroke1 trial

A Dose-Escalation Safety Study of Urokinase for Thrombolysis in Patients With Acute Ischemic Stroke

Recruiting·CCapital Medical University·Preclinical·NCT07047326·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Urokinase thrombolysis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urokinase thrombolysis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urokinase thrombolysis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Zhengzhou University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Zhengzhou University

Urokinase thrombolysis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Stroke1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News